ADVERTISEMENT

Stay up to date every week with the european biotechnology newsletter.

✕
This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent

Stay up to date every week with the european biotechnology newsletter.

Log in here to read the desired article.

This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent
go to the article

go back to the homepage

  • Subscription
  • Newsletter
  • Advertise
European Biotechnology Magazine
biocom_logo
  • Latest news
  • Background
  • Opinion
  • The Mag
    • Issues
    • Special
    • Corporate publications
    • Subscribe
  • Euro Biotech Guide
  • Market Place
    • Products
    • Sponsored Publications
    • Advertise
  • Associations
  • Service
    • Newsletter
    • Contact Us
    • Editorial Team
  • Events
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

ADVERTISEMENT

Athens Kos Biotechnology
Venture capital

Kos Biotechnology raises US$123m for Greek life sciences fund

Kos Biotechnology Partners has raised US$123m (€106m) for its inaugural global life sciences fund, marking a notable step for Greece’s still young biotechnology financing ecosystem. more ➔

hearing loss gene therapy
gene therapy

Sensorion drops a gene therapy asset because of Regeneron

Sensorion has selected SENS-601, its gene therapy candidate for GJB2-related hearing loss, as its lead gene therapy program after filing clinical trial applications in France and Canada. The French biotech … more ➔

ADVERTISEMENT

Molecular glue
Licensing

Novartis and Orionis get stuck in with new “molecular glue” R&D deal worth up to $1.4bn

Orionis and Novartis have expanded an existing deal to develop “molecular glue”, with a new agreement worth up to $1.4 billion, aiming to stick small molecule drugs onto challenging and elusive drug … more ➔

Wall street
Financing

Heidelberg-based Veraxa ventures onto Nasdaq in turbulent market environment

Veraxa Biotech, an oncology company spun out of research at the European Molecular Biology Laboratory (EMBL), has completed its merger with SPAC company Voyager Acquisition Corp. and will be trading … more ➔

Neurons
Research

Scenic Biotech joins Michael J. Fox LRRK2 consortium with a novel lysosomal bet on Parkinson’s

Scenic Biotech has joined the Michael J. Fox Foundation’s LRRK2 consortium to test a Parkinson’s disease approach that targets neither LRRK2 nor GCase directly. more ➔

European Biotechnology

1 / 4
EBM 2026_cover

The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. … more ➔

Get a free sample copy | Abo
2 / 4
10/3/26 mw: Satz, PDF an JE, danach zu Andi

The Spring 2026 issue of European Biotechnology Magazine presents a list of start-ups to watch in 2026 and explores other fascinating topics such as: Can biotechnology finally fix infertility? Can … more ➔

Get a free sample copy | Abo
3 / 4
EB425_Cover

Europe is losing much of its expertise in deep tech and life sciences to the US. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔

Get a free sample copy | Abo
4 / 4
EB325_cover

Investors are showing enormous interest in the topic of longevity, as well as in combating chronic diseases. This is because these diseases have a negative impact on life expectancy. The USA and China … more ➔

Get a free sample copy | Abo

ADVERTISEMENT

© AI
european-biotechnology-logo

NEWSLETTER


Stay up to date with the biotech industry!

Once a week, european-biotechnology.com brings you up to date on the latest developments in the biotech industry. In our free newsletter, you will find the latest news from business, research and politics, as well as lots of useful information and job vacancies.


Subscribe to our free newsletter!Subscribe here

Sanofi bid
clinical data

Sanofi’s $11.6bn Bioverativ purchase looks hit-and miss after phase 3 rare diseases drug runs into trouble

Sanofi’s $11.6bn Bioverativ acquisition is back under scrutiny after riliprubart, a rare disease drug inherited through the deal, failed a phase 3 CIDP study. While Altuviiio has become a blockbuster, … more ➔

circular RNA circio
fundraising

Circio completes NOK300m financing to fund circular RNA platform development

Oslo-based Circio has completed a NOK300m (€27m) financing round, extending its runway to the end of 2030 and giving the company funds to advance its circVec circular RNA expression platform toward … more ➔

ADVERTISEMENT

Sponsored Publications

image
Mammalian cell culture

3PBIOVIAN expands its mammalian capacity with an additional 2,000 L bioreactor

3PBIOVIAN has added an additional 2,000-liter single-use bioreactor for mammalian cell culture, further strengthening its industrial capacity and reinforcing its value proposition as a CDMO partner … more ➔

APPOINTMENTS

all appointments

Reb.com_Rezon_Bio_Ralf OttoRezon Bio
Rezon Bio

Biotechnology expert joins CDMO

Dr Ralf Otto, a former manager at Boehringer Ingelheim and Rentschler, has been appointed as the new Chief Operating Officer of the …
more ➔

tk.de_Immunic-CEO_Erik_LundgrenImmunic AG
Immunic

MS expert takes the helm

Erik Lundgren assumed his role as the new CEO of Immunic. He succeeds Dr Daniel Vitt, who will continue to oversee the biotech company’s …
more ➔

eb.com_Marc_Clausse _SantheraSanthera
Santhera

New CCO starts in June

Marc Clausse will take up his new role as Chief Commercial Officer at Santhera Pharmaceuticals (SIX: SANN) at the beginning of June. …
more ➔

tk.de_Andrea_Pfeifer_AC_Immune_PorträtAC Immune SA
AC Immune

Co-founder and CEO steps down

Dr Andrea Pfeifer, long-serving CEO and co-founder from AC Immune, has decided to retire. AC Immune’s Board of Directors has appointed …
more ➔

AlzeCure stock price
licensing

AlzeCure shares soar over 300% after Eli Lilly strikes Alzheimer’s deal worth over $1bn

Swedish biotech AlzeCure Pharma entered a collaboration and licensing agreement with Eli Lilly, granting the biopharma giant global rights to its Alzheimer’s disease candidate Alzstatin (ACD680). Under … more ➔

ADVERTISEMENT

obesity drug zealand boehringer
obesity

Boehringer/Zealand obesity drug delivers Phase III weight loss, but side effects raise questions

Boehringer Ingelheim has reported new Phase III data for survodutide, its once-weekly dual GLP-1/glucagon receptor agonist for obesity, highlighting reductions in body weight, visceral fat and liver … more ➔

Parkinson GBA1
clinical data

Bial drops pariceract after Phase IIb failure in GBA-associated Parkinson’s

Portuguese drugmaker BIAL has discontinued development of BIA 28-6156, also known as pariceract, after a Phase IIb study failed to show that the oral therapy could slow progression in patients with GBA-associated … more ➔

All news
newsletter_link

EVENT


European Biotech Magazine 960x540px
July 21 - July 23in Amsterdam, Netherlands

Join the only Neoantigen-Specific Summit this July

The 9th International Neoantigen Summit returns to Amsterdam to bring together the only dedicated forum for end-end neoantigen development. From validation and identification to clinical readouts, biomarker strategy, personalised and off-the-shelf approaches – this is your only platform dedicated to sharing critical developments in neoantigen the ... ➔

Knowbio GmbH
  • Link to LinkedIn
  • Link to Instagram
  • Contact
  • Imprint
  • Privacy policy
Scroll to top Scroll to top Scroll to top